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Amyotrophic lateral sclerosis (ALS) is a rapidly progressive, adult-onset neurodegenerative disease characterized by selective dysfunction and
death of motor neurons in the brain and spinal cord. The disease is typically fatal within 3–5 years of symptom onset. There is no known cure and
only riluzole, which was approved by the FDA in 1996 for treatment of ALS, has shown some efficacy in humans. Preclinical insights from model
systems continue to furnish ample therapeutic targets, however, translation into effective therapies for humans remains challenging. We present an
overview of clinical trial methodology for ALS, including a summary rationale for target selection and challenges to ALS clinical research.
© 2006 Elsevier B.V. All rights reserved.Keywords: Amyotrophic lateral sclerosis; Clinical trial; Preclinical model; Drug evaluation1. Introduction
Because ALS is a uniformly fatal disease for which no
adequate treatment exists, there is a pressing need to develop
effective therapies. Preclinical research aimed at elucidating
mechanisms of disease in large part specifies the kind of
therapies that may be effective against motor neuron demise, and
increasingly identifies specific candidate compounds for testing.
Taking a drug from “bench-to-bedside” is an enormously costly
and complex process. Here, we present an overview of important
features in the discovery, development, and validation of
disease-modifying therapies and interventions for ALS.
2. Rationale for target selection
2.1. Disease pathogenesis
The pathologic hallmark of ALS is the selective loss of
motor neurons in the cortex, brainstem, and spinal cord.
Determining molecular and cellular mechanisms that contextu-
ally favor motor neuron death in ALS is the starting point in⁎ Corresponding author. Neurology Clinical Trials Unit, Massachusetts
General Hospital, Building 149, 13th Street, Room 2271, Charlestown, MA
02129, USA. Fax: +1 617 724 7290.
E-mail address: adibernardo@partners.org (A.B. DiBernardo).
0925-4439/$ - see front matter © 2006 Elsevier B.V. All rights reserved.
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is not completely understood and while much controversy
remains about its molecular and biochemical biology, there is
increasing consensus that multiple mechanisms of injury
converge as the disease progresses and that caspase activation
is a final pathway of cell death [1–3].
Important early insights into ALS pathogenesis resulted from a
Paracelsian approach, in a phrase, that used the “patient as
textbook” to learn about the disease. Studies in serum,
cerebrospinal fluid (CSF), and post-mortem tissue implicated
four principle mechanisms of injury: oxidative stress, excitotoxi-
city, axonal transport defects and protein mishandling. These
pathways have been extensively explored in the context of cellular
and/or animal systems used both to model disease and as major
platforms for drug discovery. Thesemodel systems have provided
further insights about potential contributors to disease including
mitochondrial dysfunction, apoptosis, and inflammation.
2.2. Rationale for oxidative stress hypothesis
The hypothesis that oxidative damage is central to ALS was
prompted by the discovery that mutations in a key cellular
antioxidant, superoxide dismutase (SOD1), can cause ALS.
While the majority of ALS cases are sporadic, about 10% of
cases are inherited as an autosomal dominant trait and of these,
25% arise due to mutations in the gene encoding SOD1 [4].
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updated list see the online database at www.alsod.org).
Transgenic mice bearing point mutations found in humans,
including the first and most widely studied SOD1G93A mutant
[6], develop progressive motor neuron disease with clinical and
pathologic features of the human disease [6–9]. The primary
biochemical function of SOD1 is to convert superoxide, a toxic
oxygen species generated by mitochondrial respiration, into
hydrogen peroxide and water. While oxidative damage is an
attractive proposal for the toxicity of mutant SOD1, it has been
difficult to establish in experimental paradigms. SOD1 null
mutant mice do not develop disease [10], and the level of
enzyme activity is unchanged or elevated in mutant models that
do develop disease [9], suggesting that diminished SOD1
activity does not cause motor neuron disease. Toxic copper-
mediated chemistries involving aberrant substrates for mutant
SOD1, including peroxynitrate [11,12] and hydrogen peroxide
[13], have been proposed. Altering copper-loading onto SOD1
[14,15] or peroxynitrate precursors levels by manipulating
nitric-oxide synthetase [16,17], however, had no effect on
toxicity, suggesting that these aberrant reactions are not likely to
have a major role in SOD-mediated disease.
Whether the primary toxicity of SOD1 mutants is oxidative
remains uncertain. Some studies suggest that the toxicity of
mutant SOD1 may relate to secondary effects of protein
aggregates, including disruption of apoptotic regulatory
mechanisms within cells (see below for discussion). Certain
evidence, though, implicates oxidative injury in the pathogen-
esis of ALS. Studies of serum, CSF, and human post-mortem
tissue have found increased markers of oxidative damage [18–
21]. 8-hydroxydeoxyguanosine (8-OHDG), a marker of oxida-
tive damage to DNA, is present in the blood and CSF of ALS
patients and increases significantly with disease progression
[22]. Clinical efforts to address oxidative damage currently
include an early phase trial of the manganese porphyrin
AEOL10150, which acts as a free-radical scavenger [103]
(Table 1 lists all ongoing human trials).
The timing of oxidative stress in the disease process and the
relevant cell type(s) responsible for elaborating reactive species
are not known. There is biochemical and pathologic evidence,
however, favoring involvement of this pathway in motor neuron
dysfunction, and a variety of anti-oxidant compounds already
exist. Thus, modulating oxidative stress remains a reasonably
promising approach to neuroprotection and development of
drugs to slow the progression of ALS.Table 1
Current Clinical Trials in ALS
Compound Mechanism Clinical stage
Ceftriaxone Anti-excitotoxic Phase I–III
Minocycline Anti-inflammatory, anti-apoptotic Phase III
AEOL10150 Anti-oxidant Phase I
Arimoclomol Protein misfolding Phase II
High-Dose Coenzyme Q Mitochondrial dysfunction Phase II
Sodium phenylbutyrate Histone deacetylase inhibitor Phase II
Ritonavir and hydroxyurea Anti-apoptotic Phase II
Thalidomide Anti-apoptotic Phase II2.3. Rationale for glutamate hypothesis
The neurotransmitter glutamate can induce excitotoxic injury
by accumulating at the synapse and causing repetitive
depolarizations, cellular edema from sodium influx, and loss
of calcium homeostasis in the post-synaptic neuron [23,24].
Compelling evidence for glutamate-mediated injury to motor
neurons in ALS is the ability of riluzole to prolong survival in
human trials [25,26]. Riluzole is thought to inhibit release of
glutamic acid and act at the calcium-permeable NMDA receptor
and voltage-gated sodium channels to attenuate cellular
responses to glutamate. Defective glutamate handling in ALS
was initially suspected based on markedly elevated levels of
glutamate in the CSF of affected individuals [27–29] and the
finding of impaired glutamate transport associated with loss of
the EAAT2 transporter [30]. Five subtypes of glutamate
transporters have been identified, but the astrocytic EAAT2
transporter buffers ∼90% of the extracellular glutamate
surrounding motor neurons [31,32]. Loss of astrocytic EAAT2
protein has been found in 60% of patients with sporadic ALS
[31]. A mutation in the EAAT2 coding region detected in one
patient with sporadic ALS was found to alter membrane
targeting for the protein and impair glutamate uptake [33].
Interestingly, SOD1 mutants are associated with functional loss
of EAAT2 in mice [34]. Because motor neurons possess a
relative lack of calcium buffering proteins [35], and the
configuration of the AMPA receptor on these cells confers
increased permeability to calcium [36], motor neurons may be
especially vulnerable to excitotoxic injury. Thus, targeting
glutamate-mediated injury is a uniquely promising approach to
drug development for ALS. Recently, Rothstein and colleagues
performed an elegant screen of FDA-approved drugs in vitro to
identify compounds that could up-regulate EAAT2 expression
[37]. Many β-lactam antibiotics turned out to be potent inducers
of EAAT2 expression, however, ceftriaxone showed the added
benefit of increasing brain expression and activity of EAAT2 in
animals and a demonstrated a clear neuroprotective effect in
both in vitro and in vivo models of motor neuron disease.
Whether ceftriaxone confers the same benefit in humans will be
determined in an upcoming clinical trial in patients with ALS.
Another approach would be to concentrate efforts on the sole
drug that has proven efficacy against ALS. A better under-
standing of the drug–receptor interactions that mediate
riluzole's beneficial effect may bring to light rational modifica-
tions to its structure that could improve efficacy. In all events,
since a mechanism of injury can be described from a ligand–
receptor interaction at the cell surface through multiple well-
described downstream signaling cascades, the glutamate injury
pathway offers a promising array of potential targets for
therapeutic intervention.
2.4. Rationale for axonal dysfunction hypothesis
A pathologic hallmark of ALS is the accumulation of
neurofilaments, abundant cytoskeletal components, in the soma
and proximal axons of motor neurons [38]. In both human ALS
and SOD1 transgenic animals, the largest caliber, most
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1% of sporadic ALS cases have small deletions or insertions in
the repetitive tail domain of the neurofilament heavy gene [40].
Moreover, transgenic mice bearing mutant neurofilament light
gene display axonal disorganization and selective motor neuron
death [41–43]. Manipulating expression levels of neurofilament
subunits has a robust effect on disease in the SOD1 mouse [44–
46], suggesting that neurofilament organization could be a
factor in the selective vulnerability of large-caliber motor
neurons. This finding also hints at the therapeutic potential of
modulating neurofilament content and/or organization to slow
the disease. The sensitivity of motor neurons to altered axonal
dynamics is underscored by mutations in kinesins [47],
peripherin [48], and dynactin [49] that cause selective motor
neuron degeneration. Although these findings are suggestive,
no clear mechanism of injury or therapeutic approaches have
emerged from preclinical studies yet.
2.5. Rationale for protein mishandling hypothesis
Protein aggregates form in several neurodegenerative
diseases but there is debate over whether they are causative,
harmless epiphenomena, or potentially beneficial sinks to
sequester toxic abnormal proteins in disease states. Ubiquinated
protein aggregates are found in upper and lower motor neurons
in sporadic as well as familial forms of ALS [50,51]. In
transgenic models, SOD1-immunoreactive inclusions accumu-
late in motor neurons and astrocytes before the onset of motor
dysfunction [52]. These aggregates also include neurofila-
ments, glial fibrillary acidic protein, two neuronal glutamate
transporters, bcl-2, and proteins involved in chaperone and
proteosome functions [53,54], potentially linking these aggre-
gates to a number of pathogenetic mechanisms including
axonal dysregulation, glutamate mishandling, apoptosis, and
impaired folding of functional proteins essential to motor
neurons and/or clearance of potentially dysfunctional ubiquitin-
tagged proteins. In addition, aggregations within mitochondria
may contribute to impaired cellular energetics and potentially
set off disease-initiating damage within motor neurons [55,56].
The toxicity of aggregates is suggested by the finding that over-
expression of heat-shock proteins, molecular chaperones, can
reduce mutant SOD1 aggregation and enhance the survival of
cultured motor neurons [57–59]. Induction of heat-shock
proteins by arimoclomol increased the life span of
SOD1G93A mice by 22% [60], prompting the current clinical
Phase II trial in humans (www.clinicaltrial.gov). Up-regulating
the expression of individual or combinations of heat-shock
proteins and their co-factors may be a valid neuroprotective
strategy for motor neuron disease, especially in light of the
characteristically high threshold motor neurons have for
mounting a heat shock response to stress [61].
2.6. Rationale for mitochondrial dysfunction hypothesis
Evidence that mitochondria may participate in ALS comes
chiefly from model systems. Neuropathologic studies of motor
neurons in SOD1 transgenic mice reveal mitochondrialvacuolation [9,62] prior to cell loss [63]. SOD1 accumulates
in vacuolated mitochondria [64]. Mitochondrial proteins and
lipids display oxidative damage and respiratory chain com-
plexes show reduced activity and ATP synthesis [65]. Apoptotic
regulation within motor neurons may be disrupted due to release
of mitochondrial cytochrome C into the cytosol [1,66], or
trapping bcl-2 within mitochondrial SOD1 aggregates [53].
Expression of mutant SOD1 in the NSC34 motor neuronal cell
line results in swollen mitochondria, impaired activity of
respiratory chain complexes II and IV, diminished ATP
production, and protein alterations [67,68], strengthening the
impression that respiratory defects could be cell-autonomous in
vivo. Observations in sporadic ALS support a role for
mitochondrial dysfunction, including altered mitochondrial
morphology in liver [69,70] and muscle [71]; a high frequency
of mitochondrial DNA mutations in cortical motor neurons
[72]; multiple mutations and decreased mitochondrial DNA in
muscle and spinal cord [73], and reduced complex IVactivity in
spinal motor neurons [74]. Mitochondrial DNA mutations,
accumulated over time in affected tissues, have been postulated
to play in role in the pathogenesis of ALS, however, evidence
diverges over whether these mutations in fact impair mitochon-
drial respiration [75,76]. Taken together, the evidence impli-
cating mitochondrial dysfunction in ALS is indirect. It is
important to stress, however, that mitochondria sit at the nexus
of several cell processes that may be relevant to motor neuron
disease, including cytochrome C-mediated apoptosis, impaired
cell bioenergetics, and the production of reactive oxygen
species. Thus, compounds with mitochondrial effects have the
potential to be rewarding targets for therapeutic development.
2.7. Rationale for apoptotic hypothesis
An increasing body of evidence suggests that the final cell
death pathway for motor neurons in ALS is apoptotic. Studies of
human post-mortem tissue demonstrate TUNEL-positive
degenerating motor neurons [77,78]; increased levels of
apoptosis related molecules [79]; significantly increased levels
of caspase 1 and 3 activity in spinal cord [77], and altered
balance between pro- and anti-apoptotic regulatory proteins
favoring apoptosis [80]. Cellular disease models suggest that
motor neurons expressing mutant SOD1 are more likely to
undergo apoptosis under conditions of oxidative stress [81]. In
the mutant SOD1 mouse model, caspase 1 and caspase 3
expression is increased in the spinal cord of symptomatic mice,
and the balance of bcl2 protein family members shifts in a
direction favoring apoptosis [82,83]. The therapeutic potential
of apoptotic inhibitors is underscored by neuroprotective effects
of genetic manipulations in SOD1 transgenic mice to over-
express anti-apoptotic molecules [84], exposure to caspase
inhibitors in cellular models [85], and intraventricular admin-
istration of a broad spectrum caspase inhibitor to mutant SOD1
mice which demonstrated that chronic caspase inhibition can
significantly prolong survival [82]. Pure caspase inhibitors have
not been clinically assayed. Compounds that attenuate cell
death through other means potentially include minocycline,
which has been show to inhibit release of mitochondrial
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and ritonavir, which abolishes apoptotic response to oxidative
stress in neurons [86]. Minocycline and ritonavir are currently
being evaluated in clinical studies with ALS patients.
2.8. Rationale for inflammatory hypothesis
The presence of activated microglia is a histological feature
of ALS and SOD1-mediated murine disease [87,88]. In mice,
microglial activation precedes clinical weakness and motor
neuron loss [89], and chronic stimulation of innate CNS
immunity exacerbates motor neuron disease in mice [90].
Activated microglia elaborate several potentially neurotoxic
molecules, including reactive oxygen and nitrogen species,
proteases, and pro-inflammatory cytokines that amplify inflam-
mation. The profile of inflammatory cytokines and enzymes up-
regulated in the spinal cord or CSF of ALS patients (IL-6, IL-
1β, cyclo-oxygenase 2 (COX2), and prostaglandin E2 (PGE2))
[91–93] and in the spinal cord of mutant SOD1 mice (IL-1β,
TNFa, COX2, PGE2) [94] tends to implicate microglial
involvement. Microglia conditioned by CSF from ALS patients
act to increase the vulnerability of cultured neurons to glutamate
toxicity, an effect blocked by minocycline [95]. Further,
minocycline, an inhibitor of microglial activation, slows disease
progression in mutant SOD1 mice [96–99]. Non-neuronal cells,
including microglia, may be especially relevant to SOD1-
mediated disease. Restricted neuronal expression of mutant
SOD1 does not produce motor neuron degeneration in animals
[100,101]. In chimeric mice, motor neurons expressing mutant
SOD1 are unaffected if surrounded by normal non-neuronal
cells, whereas normal motor neurons surrounded by non-
neuronal cells expressing mutant protein developed ubiquiti-
nated intraneuronal deposits, a feature typical of diseased
neurons [102]. Preclinical studies of inflammatory mediators in
motor neuron degeneration have furnished a number of cellular
and molecular targets. Current clinical initiatives to address
inflammatory aspects of ALS include the glutamic acid
derivative thalidomide, which reduces the synthesis of TNF-α
[104]? and minocycline. Whether immunomodulation has a
beneficial effect on human disease remains to be seen.
3. Strengths and weaknesses of in vitro platforms for drug
discovery
In vitro systems have refined our insight into disease
mechanisms and provided useful platforms to identify potential
therapeutic approaches. These include purified primary cultures
of motor neurons from embryonic rat [105], co-culture systems
of motor neurons from embryonic mice plated on a glial feeder
layer of cortical astrocytes [106], and organotypic spinal cord
slices from post-natal rats [31,107]. Additionally, cell lines
expressing mutant SOD1 have been developed with motor-
neuron like cells (NSC34) [108] and HeLa cells [109]. Prior to
1995, some 50 drugs and trophic factors were evaluated in
culture systems [110], furnishing preclinical data for a number
of investigational new drug trials. Currently, an expanding
range of receptor and signaling targets together with thedevelopment of combinatorial chemistry, compound libraries,
and high-throughput screening techniques stand to increase the
number of potential drugs exponentially-far beyond the range of
what can actually be tested. Thus libraries to be tested in high-
throughput screening assays will have to be rationally designed
in order to yield practical results. An initial cost-efficient
approach is to screen compounds that are already FDA-
approved for other indications. The Neurodegeneration Drug
Screening Consortium, for example, tested 1040 FDA-
approved drugs in cell-based models of neurodegeneration
[111], an effort which established groundwork for the pending
clinical trial of ceftriaxone in ALS. Other kinds of compound
libraries can be constructed, based on any number of desired
properties-CNS-penetration, for example. Multiple-well micro-
titer formats for automated high throughput screens can be
designed to detect changes in target protein levels by
chemiluminescent reporters, like luciferase. Lower throughput
manual assays may permit greater complexity of experimental
design, including more sensitive quantitation of cell death.
Potential limitations of in vitro models may include biochemical
or structural differences between adult and embryonic cell
types, for example if disease-relevant proteins or their post-
translational modification are developmentally regulated. Ad-
ditionally, all culture systems with the possible exception of
spinal cord explants do not replicate the metabolic interactions
likely to be operating in vivo. This is especially relevant to cell
death since it is increasingly apparent that microglia, motor
neurons, astrocytes, and endothelial cells likely form a
metabolic unit that contributes to the demise of motor neurons
in disease states [112]. Overall, the power of in vitro models to
investigate disease mechanisms and search for promising
therapies far outweighs potential limitations.
4. Strengths and weaknesses of animal model for drug
discovery
Several experimentally induced mutations – G93A, G37R
and G85R – have been developed in transgenic mouse models,
however, the SOD1G93A mutant is primarily used for
therapeutic research. The SOD1G93A mutant generally reca-
pitulates human disease, including cardinal findings of motor
neuron loss, microgliosis and astrocytosis [6,118] and is a
powerful tool for dissecting the biology of motor neuron
disease. The major weakness of animal models for ALS thus far
has been the de facto failure of these models to predict response
in humans. Riluzole, first demonstrated to be effective in
humans was later shown to be effective in the SOD1G93A
mouse model. As experience as shown, the converse does not
always hold and a number of compounds found to be effective
in this model failed in humans, including vitamin E [113],
gabapentin [114], topiramate [115], celecoxib [116], and
creatine [117]. The reasons for discordant results between
mouse and human trials are not fully understood but may relate
to inherent differences between the mouse and human disease.
For example, the vacuolar degeneration seen in SOD1 models is
not a feature of human disease. Unlike ALS patients, transgenic
mice over-express mutant protein 5- to 15-fold, and life span
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species-specific differences may be important, such as differ-
ences in microglial activation. Comparability of pharmacoki-
netics, routes of delivery, timing of treatment, and relevance of
the familial disease model to sporadic disease are all issues of
potential importance for interpreting and applying data from
mouse studies to humans. Despite its track record of poor
predictive ability, the transgenic mouse model remains a
critically important tool both to unravel the complex stages of
motor neuron disease, and to pursue new therapeutic approaches.
5. Translation to humans
5.1. Preclinical toxicology
The FDA currently requires toxicology studies in animals
for any investigational new drug application to support the
safety of a new compound for use in humans (see Content and
Format of Investigational New Drug Applications (INDs) for
Phase 1 Studies of Drugs Including Well Characterized,
Therapeutic, Biotechnology-Derived Products). Information
about toxicities and toxicokinetics in animals guides subse-
quent trial design, for example by determining criteria to
exclude patients who would be at high risk for developing
anticipated toxicity and incorporating appropriate monitoring.
The cost of acquiring these data can mount to $1,000,000 or
more, making these studies prohibitive for any but the most
promising compounds. Thus, the number of compounds that
can ever be brought to this stage of development is limited by
the availability of resources.
5.2. Phase I
Phase I trials introduce a new investigation compound into
humans. Typically these are small trials (less than 30 subjects),
designed to assess safety, dose-ranges, and pharmacokinetics.
Starting dose selection is a critical issue in translating preclinical
findings into human trials. Factors that may affect optimal dose
determination relate to a compound's pharmacokinetics and
bioavailability, which may vary between species or with route
of administration (e.g., oral versus intraperitoneal). Interactions
with other commonly encountered medications in humans may
also affect metabolism and thus dose selection.
Animal data tend to be extrapolated to estimate a starting dose
with some minimal activity that also has minimal risk of side
effects. Human Equivalent Dose (HED) calculations, an algo-
rithm to determine the maximum recommended starting dose, are
normally based on body surface area conversions mg/m2. Other
parameters for drug extrapolation are just as appropriate and, in
specific instances where there are similar mg/kg doses across
species, the HED rules stipulate that body weight may be used.
The calculated dose can change dramatically depending on which
parameter is used. For example, the most effective neuroprotec-
tive dose of creatine in the SOD1G93A mouse studies was 2% of
the diet [119], corresponding to 30–35 g/d in ALS patients
weighing 70 kg. Subsequent negative trials of creatine in humans
[117,120], however, started at doses of 5 and 10 gm/kg based onbody surface area conversions, legitimately raising the question of
whether these studies may have been under dosed.
Ideally, several different doses would be selected for
evaluation in sequential dose-escalation cohorts with careful
safety monitoring during inter-cohort intervals, or alternately by
randomization of subjects by dose. Investigating a single dose
runs the risk of missing adverse events that could surface in later
trials, as well as the more remote risk of missing large effects.
Small phase I dose-ranging trials in “typical” ALS patient
cohorts (heterogeneous, on riluzole, etc.) may provide the most
useful set of data for planning subsequent clinical trials,
however, dose-ranging trials are often performed in healthy
controls rather than in the target study population to assess
subacute toxicity and pharmacokinetic parameters.
5.3. Phase II trial design
Phase II studies are designed to assess long term safety and
refine pharmacokinetic data, determine optimal dose, and
gather preliminary data on efficacy. Designing good phase II
studies in ALS is challenging due to inherent variability
between subjects that can obscure small treatment effects, the
relative insensitivity of current outcome measures, and the fact
that the length of treatment needed to observe even preliminary
efficacy is not known in advance. Traditional phase II trials
typically require 100–150 subjects, usually randomized and
placebo-controlled, studied over 9–12 months. Because phase
II trials are quite resource intensive, several innovations meant
to increase the efficiency of these trial are being actively
explored by a number of research communities, including
proof-of-concept testing, lead-in periods, futility designs and
statistical modifications that attempt to minimize the chances of
missing an effective therapy.
By virtue of its lethality and rapid progression, ALS is
appropriate for proof-of-concept testing of potential thera-
peutics, where a drug is administered for a short period and
effects on measurable markers of disease are sought. What
constitutes a reasonable length of treatment, though, can be
difficult to decide in advance. Additionally, the inherent
variability between subjects may obscure a smaller response
to disease-modifying therapy especially in the short run, so that
these trials still require large numbers of subjects and a control
group. Finally, identifying and validating markers of neurode-
generation that vary with disease progression and disease-
modifying treatment are necessary first steps to instituting
proof-of-concept trials. While no validated surrogate markers
exist for ALS, promising work in MR-spectroscopy, neuro-
physiologic data, and proteomics and metabolomics suggest
that appropriate markers may be on the horizon (see below).
Lacking valid surrogate markers, certain functional measures
are employed as study endpoints and have proven to be quite
useful for ALS clinical trials. Newer trial designs that
incorporate a lead-in period off-drug may improve the accuracy
of functional measures. Lead-in design is well-suited to
outcome measures that have linear characteristics and correlate
with disease outcome, such as the ALS Functional Rating Scale
(ALSFRS) or forced vital capacity (FVC) [121,122]. Observing
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allow slope estimation for individual subjects, thus facilitating
detection of a treatment response. Because lead-in studies are
more efficient at detecting treatment effects, smaller samples
sizes can be used.
In cancer drug development, open-label, single-arm phase II
trials are used to assess safety and determine whether an agent
shows sufficient efficacy to warrant a full phase III evaluation.
An assessment of no effect, or no “worthwhile” effect, of a
given compound essentially demonstrates the futility of
proceeding with further clinical testing. In futility analyses it
is important to minimize Type I errors, i.e., false negatives, in
order to minimize the risk of missing a potentially effective
therapy. Multi-arm futility designs evaluating several different
therapies may speed up the process of identifying “minimally
worthwhile” compounds for further study, thus potentially
compressing the research and patient time taken up by
compounds that do not work.
Another way to minimize the risk of missing a potentially
good drug is to modify the P value conventionally used for
statistical significance [123]. Setting a standard two-sided P
value at 0.05 effectively minimizes the risk of taking a truly
ineffective drug forward to about a 1 in 40 chance. Alternatively,
setting a one-sided p at 0.10 minimizes the risk of abandoning a
good drug in phase II testing. A one-sided alternative hypothesis
assumes that there is a directional difference in outcome (drug A
improves outcome more than drug B), whereas two-sided does
not specify the direction (treatment could be better or worse with
respect to primary outcome). Thus, for ALS clinical trials, it may
be reasonable to statistically structure phase II trials with one-
sided P values of 0.10 to avoid the worst-case scenario of
missing a good drug, understanding that this confers a 10%
chance of proceeding to phase III with an ineffective drug. It
is of course disappointing and resource-intensive when initial
efficacy findings from phase II are not confirmed at later
stage evaluation, as was the case for gabapentin [114] and
BDNF [124]. The severity and fatality of ALS, however, may
warrant reconsideration of statistical biases that increase the
likelihood of missing the next effective therapy to treat this
disease.
Data from well-designed early phase trials is critical
planning later-stage efficacy trials. Conventional phase II
studies provide data on drug activity, magnitude of effect size,
optimal dose, and higher resolution toxicity information.
Concerns about the efficiency of phase II studies have prompted
re-evaluation of optimal design strategies which await use and
validation by the ALS community.
5.4. Phase III trial design
Phase III trials are large trials intended to determine whether
a treatment is effective and to establish safety data. Although
relevant to other phases as well, the important variables
monitored in phase III trials are outcome measures, safety,
and prognostic factors. Outcome, or efficacy, variables define
the end point of the study. Prolonging life is obviously a
desirable therapeutic goal, but using survival as an endpoint canbe problematic. To demonstrate a meaningful effect on
mortality, trials must enroll large numbers of ALS patients
(250 or more subjects per arm) and follow them over long
periods (12 to 18 months), thus limiting the number of
compounds that can be tested. And while survival seems
unequivocal as an endpoint, it may be affected by the use of
non-invasive ventilatory techniques, nutritional support via
gastrostomy tube, or care within a multi-disciplinary ALS
clinic. Constrained resources, limited numbers of eligible
patients, and variations in survival due to ancillary support
have motivated researchers to define meaningful surrogate
outcome measures that are objective, reproducible, and valid
across trials of varying duration [122]. At present, no validated
surrogate measure directly correlates to pathophysiologic
changes nor is it known whether any given surrogate marker
is sensitive to disease-modifying therapy [125]. Several clinical
markers are used, including various muscle tests, pulmonary
testing (FVC), and a standardized functional rating scale
(ALSFRS). An analysis of subjects enrolled in a clinical trial
of topiramate suggested that declines in FVC and ALSFRS
were linear and independent predictors of survival [122].
ALSFRS was also found to correlate with survival in a study of
ALS clinic patients [126]. A recent negative trial of pentoxifyl-
line in patients with ALS, however, found a significant
discrepancy between survival and changes in functional
measures including ALSFRS, casting some doubt on the
adequacy of these measures as surrogate endpoints in phase
III trials [127]. Potential pathophysiologic markers include
estimation of motor unit number (MUNE), transcranial
magnetic stimulation (TMS), and magnetic resonance spectros-
copy (MRS) of motor cortex. Experience with MUNE suggests
that it can show a higher percentage change than clinical
measures and can decrease earlier than clinical measures like
grip strength, thus making it a potentially excellent surrogate
endpoint for efficacy trials [128,129]. TMS and variations in
MR spectra, while promising, are not yet appropriate to use for
trial endpoints. Finally, proteomics and metabolomics, compre-
hensive inventories of proteins and small molecules present in
cells and tissue, will likely identify biomarkers in many disease
states. Proteomic studies in CSF [130] and metabolomic studies
in plasma [131] from subjects with ALS suggest that
characteristic profiles may exist for the disease, however,
whether significant change occurs with disease progression is
not yet known.
Baseline data includes information to determine whether the
subject is representative of the study population and meets
inclusion/exclusion criteria for the study. These data usually
include variables that may correlate with overall disease
progression and serve as prognostic factors of disease outcome.
In ALS, variables like gender, age at onset, duration of disease,
bulbar features, for example, may be of prognostic value.
Randomization typically ensures that each group of subjects is
on average alike, to minimize the possibility that an observed
treatment effect is due to inherent differences between groups.
Stratifying patients with similar influencing variables allows for
subgroup analyses to determine the relationship between
prognostic variables and outcomes, and permits a balancing
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study outcomes. Failing to take account of prognostic variables
may result in perceived effects unrelated to treatment. For
instance, enrolling a disproportionate number of elderly
subjects or subjects with significant bulbar dysfunction can
result in poorer trial outcomes that do not truly reflect on the
efficacy of the trial drug. Furthermore, drop-out rates can affect
the balancing effect of randomization, thus it is important for
study monitoring to periodically review baseline variables in
treatment and control arms to identify potential inequities in
prognostic variables between the groups that could affect the
interpretation of test results.
5.5. Effect size
The difference in a primary outcome between placebo and
drug is considered the effect size. With limited resources, one
tends to look for larger effect sizes to reduce the number of
patients needed to reach significance and to eliminate drugs
with no significant impact on disease. The number of failed
trials in ALS perhaps prompts reconsideration of this bias.
Smaller effect sizes may be a more realistic goal for efficacy
trials in ALS. For example, a 15–20% reduction in the rate of
decline of FVC may be a meaningful treatment effect because it
correlates to a measurable increase in survival.
5.6. Patient selection
Recruiting adequate numbers of the right patients is critical
for clinical study at all phases. Underpowered early studies
provide insufficient data about toxicity, and negative results in
underpowered early phase studies can divert research interest
from potentially promising compounds. The incidence and
prevalence of ALS can impact recruitment. Additionally,
regional variations in time-to-diagnosis, referral practices, and
survival rates can affect the composition of the study groups.
For example, delays in diagnosis in some countries may bias
patient samples towards those with more advanced disease,
making determination of therapeutic potential more difficult.
Such regional differences can also pose challenges to conduct-
ing international collaborative trials. Variations in the use of
nutritional support, non-invasive ventilatory techniques, and
riluzole between national or international centers can affect
patient survival and therefore study outcomes, suggesting that
enrollment between centers must be balanced. Narrow inclusion
and exclusion criteria generally capture a relatively homoge-
neous population. While stratified or very homogenous groups
have smaller variability, and thereby the advantage of requiring
fewer patients, a disadvantage of narrowly defining inclusion/
exclusion criteria is that it may limit the generalizability of study
results across the entire disease population.
5.7. Placebo
Placebo-controlled studies have been considered an absolute
requirement for determination of real effects in clinical trials.
Uncontrolled trials may make determination of both drugbenefits and side effects difficult, and undermine the value of
early clinical findings. For example, a pronounced positive
effect found during early studies of thyroid-releasing hormone
was disconfirmed in subsequent controlled testing [132]. The
chance of being randomized into a placebo arm, however, is
emotionally difficult for this patient population given the utter
lack of effective treatment. The use of historical controls from
past trials has been limited by the amount and quality of data
available on these subjects, and worries that the “natural
history” of the disease may have changed due to changes in
supportive measures like PEG, NIPPV, and multidisciplinary
care. The Northeast ALS consortium has initiated a program to
store all placebo data from ALS trials in a common NINDS data
bank. Thus, going forward the ALS community has the
opportunity to develop, validate, and eventually utilize a
“virtual” placebo group in future ALS trials.
6. Conclusion
ALS remains a severe, life-threatening disease for which
there is no treatment to significantly slow deterioration or repair
clinical function. Preclinical research suggests that several
levels of cellular dysfunction contribute to selective motor
neuron death, whether in tandem or locked-step sequence is not
known. Thus, targeting major and minor pathways identified by
experimental injury remains the basis of drug selection for
human trials. Drug assessment in humans is a lengthy and
resource-intensive process. In the setting of constrained
resources, candidate compounds can be eliminate in early
phase studies not only on the basis of toxicity data, but also
potentially on the basis of efficacy with appropriately modified
designs. Emerging surrogate markers of disease progression
have the potential to further shorten efficacy assessments if any
marker turns out to be sensitive to disease-modifying therapy.
Until that point, large, well-designed, multi-center efficacy trials
remain the standard approach to reducing trial length and
pursuing new drugs that may have a clinically significant
impact on ALS.
References
[1] C. Guegan, M. Vila, P. Teismann, C. Chen, B. Onteniente, M. Li, R.M.
Friedlander, S. Przedborski, Instrumental activation of bid by caspase-1
in a transgenic mouse model of ALS, Mol. Cell Neurosci. 20 (2002)
553–562.
[2] M. Li, V. Ona, C. Guegan, M. Chen, V. Jackson-Lewis, L. Andrews, A.
Olszewski, P. Stieg, J. Lee, S. Przedborski, R. Friedlander, Functional
role of caspase-1 and caspase-3 in an ALS transgenic mouse model,
Science 288 (2000) 335–339.
[3] S. Sathasivam, P. Ince, P. Shaw, Apoptosis in amyotrophic lateral
sclerosis: a review of the evidence, Neuropathol. Appl. Neurobiol. 27
(2001) 257–274.
[4] D. Rosen, T. Siddique, D. Patterson, D. Figlewicz, E. Sapp, A. Hentati, D.
Donaldson, J. Goto, J. O'Reagan, H. Deng, Mutations in Cu/Zn
superoxide dismutase gene are associated with familial amyotrophic
lateral sclerosis, Nature 362 (1993) 59–62.
[5] P. Andersen, K. Sims, W. Xin, R. Kiely, G. O'Neill, J. Ravits, E. Pioro, Y.
Harati, R. Brower, J. Levine, H. Heinicke, W. Seltzer, M. Boss, R. Brown
Jr., Sixteen novel mutations in the Cu/Zn superoxide dismutase gene in
amyotrophic lateral sclerosis: a decade of discoveries, defects and
1146 A.B. DiBernardo, M.E. Cudkowicz / Biochimica et Biophysica Acta 1762 (2006) 1139–1149disputes, Amyotroph. Lateral Scler. Other Mot. Neuron Disord. 4 (2003)
62–73.
[6] M.E. Gurney, H. Pu, A.Y. Chiu, M.C. Dal Canto, C.Y. Polchow, D.D.
Alexander, J. Caliendo, A. Hentati, Y.W. Kwon, H.-X. Deng, W. Chen, P.
Zhai, R.L. Sufit, T. Siddique, Motor neuron degeneration in mice that
express a human Cu/Zn superoxide dismutase mutation, Science 264
(1994) 1772–1775.
[7] L.I. Bruijn, D.W. Cleveland, Mechanisms of selective motor neuron death
in ALS: insights from transgenic mouse models of motor neuron disease,
Neuropathol. Appl. Neurobiol. 22 (1996) 373–387.
[8] M.E. Ripps, G.W. Huntley, P.R. Hof, J.H. Morrison, J.W. Gordon,
Transgenic mice expressing an altered murine superoxide dismutase gene
provide an animal model of amyotrophic lateral sclerosis, Proc. Natl.
Acad. Sci. 92 (1995) 689–693.
[9] P. Wong, C. Pardo, D. Borchelt, M. Lee, N. Copeland, N. Jenkins, S.
Sisodia, S. Cleveland, D. Price, An adverse property of a familial ALS-
linked SOD1 mutation causes motor neuron disease characterized by
vacuolar degeneration of mitochondria, Neuron 14 (1995) 1105–1116.
[10] A. Reaume, J. Elliot, E. Hoffman, N. Kowwall, R. Ferrante, D. Siwek, H.
Wilcox, D. Flood, F. Beal, R. Brown, R. Scott, W. Snider, Motor neurons
in Cu/Zn superoxide dismutase-deficient mice develop normally but
exhibit enhanced cell death after axonal injury, Nat. Genet. 13 (1996)
43–47.
[11] J.S. Beckman, M. Carson, C.D. Smith, W.H. Kuppenol, ALS, SOD, and
peroxynitrite, Nature 364 (1993) 584.
[12] A.G. Estevez, J.P. Crow, J.B. Sampson, C. Reiter, Y. Zhuang, G.J.
Richardson, M.M. Tarpey, L. Barbeito, J.S. Beckman, Induction of nitric
oxide-dependent apoptosis in motor neurons by zinc-deficient superoxide
dismutase, Science 286 (1999) 2498–2500.
[13] M. Wiedau-Pazos, J. Goto, S. Rabizadeh, E. Gralla, J. Roe, J.
Valentine, D. Bredesen, M. Lee, Altered reactivity of superoxide
dismutase in familial amyotrophic lateral sclerosis, Science 271
(1996) 515–518.
[14] J. Wang, H. Slunt, V. Gonzales, D. Fromholt, M. Coonfield, N.G.
Copeland, N.A. Jenkins, D.R. Borchelt, Copper-binding-site-null
SOD1 causes ALS in transgenic mice: aggregates of non-native
SOD1 delineate a common feature, Hum. Mol. Genet. 12 (2003)
2753–2764.
[15] J.R. Subramaniam, W.E. Lyons, J. Liu, T.B. Bartnikas, J. Rothstein, D.L.
Price, D.W. Cleveland, J.D. Gitlin, P.C. Wong, Mutant SOD1 causes
motor neuron disease independent of copper chaperone-mediated copper
loading, Nat. Neurosci. 5 (2002) 301–307.
[16] M. Upton-Rice, M. Cudkowicz, R. Mathew, D. Reif, R. Brown,
Administration of nitric oxide synthase inhibitors does not alter disease
course of amyotrophic lateral sclerosis SOD1 mutant transgenic mice,
Ann. Neurol. 45 (1999) 314–413.
[17] M. Son, H.M. Fathallah-Shaykh, J.L. Elliott, Survival in a transgenic
model of FALS is independent of iNOS expression, Ann. Neurol. 50
(2001) 273.
[18] R. Ferrante, S. Browne, L. Shinobu, A. Bowling, M. Baik, U.
MacGarvey, N. Kowall, R. Brown, M. Beal, Evidence of increased
oxidative damage in both sporadic and familial ALS, J. Neurochem. 69
(1997) 2064–2074.
[19] M. Beal, R. Ferrante, S. Browne, R. Matthews, N. Kowall, R. Brown,
Increased 3-Nitrotyrosine in both sporadic and familial amyotrophic
lateral sclerosis, Ann. Neurol. 42 (1997) 644–654.
[20] . A.C. Bowling, J.B. Schulz, R.H. Brown Jr., M.F. Beal, Superoxide
dismutase activity, oxidative damage and mitochondrial energy
metabolism in familial and sporadic amyotrophic lateral sclerosis,
J. Neurochem. 93 (5) (1993) 2322–2325 (1087–98 61).
[21] P. Shaw, P. Ince, G. Falkous, D. Mantle, Oxidative damage to protein in
sporadic motor neuron disease spinal cord, Ann. Neurol. 38 (1995)
691–695.
[22] M. Bogdanov, R. Brown, W. Matson, D. Hayden, H. O'Donnell, F. Beal,
M. Cudkowicz, Increased oxidative damage to DNA in ALS patients,
Free Radical Biology 29 (2000) 652–658.
[23] D. Choi, Glutamate neurotoxicity and diseases of the nervous system,
Neuron 1 (1988) 623–634.[24] R. Sattler, M. Tymianski, Molecular mechanisms of glutamate receptor-
mediated excitotoxic neuronal cell death, Mol. Neurobiol. 24 (2001)
107–129.
[25] G. Bensimon, L. Lacomblez, V. Meininger, A controlled trial of Riluzole
in amyotrophic lateral sclerosis, N. Engl. J. Med. 330 (1994) 585–591.
[26] L. Lacomblez, G. Bensimon, N. Leigh, P. HGuillet, L. Powe, J.
Durrleman, V. Meininger, For the amyotrophic lateral sclerosis/riluzole
study group II. Dose-ranging study of riluzole in amyotrophic lateral
sclerosis, Lancet 347 (1996) 1425–1431.
[27] J. Rothstein, G. Tsai, R. Kuncl, et al., Abnormal excitatory amino acid
metabolism in amyotrophic lateral sclerosis, Ann. Neurol. 28 (1990)
18–25.
[28] J. Rothstein, R. Kuncl, V. Chaudry, L. Clawson, D. Cornblath, J. Coyle,
Excitatory amino acids in amyotrophic lateral sclerosis, Ann. Neurol. 20
(1991) 224–225.
[29] O. Spreux-Varoquaux, G. Bensimon, L. Lacomblez, F. Salachas, P.F.
Pradat, N. Le Forestier, A. Marouan, M. Dib, V. Meininger, Glutamate
levels in cerebrospinal fluid in amyotrophic lateral sclerosis: a reappraisal
using a new HPLCmethod with coulometric detection in a large cohort of
patients, J. Neurol. Sci. 193 (2002) 73–78.
[30] J.D. Rothstein, L.J. Martin, R.W. Kuncl, Decreased glutamate transport
by the brain and spinal cord in amyotrophic lateral sclerosis, N. Engl. J.
Med. 236 (1992) 1464–1468.
[31] J. Rothstein, M. Van Kammen, A. Levey, L. Martin, R. Kuncl, Selective
loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis,
Ann. Neurol. 38 (1995) 73–84.
[32] K. Tanaka, K. Watase, T. Manabe, K. Yamada, K. Takahashi, Epilepsy
and exacerbation of brain injury in mice lacking the glutamate transporter
GLT-1, Science 276 (1997) 1699–1702.
[33] D. Trotti, A. Rolfs, N. Danbolt, R. Brown, M. Hediger, SOD1 mutants
linked to amyotrophic lateral sclerosis selectively inactivate a glial
glutamate transporter, Nat. Neurosci. 2 (1999) 427–433.
[34] D. Howland, J. Liu, Y. She, B. Goad, N. Maragakis, B. Kim, J. Erickson,
J. Kulik, L. DeVito, G. Psaltis, L. DeGennaro, D. Cleveland, J. Rothstein,
Focal loss of the glutamate transporter EAAT2 in a transgenic rat model
of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS), Proc.
Natl. Acad. Sci. 99 (2002) 1604–1609.
[35] P. Ince, N. Stout, P. Shaw, J. Slade, C.W. Hunziker, K.G. Bainbridge,
Parvalbumin and calbinden D-28k in human motor system and in
motor neuron disease, Neuropathol. Appl. Neurobiol. 19 (1993)
291–299.
[36] T. Williams, N. Day, P. Ince, R. Kamboj, P. Shaw, Calcium-permeable
alpha-amino-3-hydroxy-5-methyl-4-isoxazole proprionic acid receptors:
a molecular deteramant of selective vulnerability in amyotrophic lateral
sclerosis, Ann. Neurol. 42 (1997) 200–207.
[37] J.D. Rothstein, S. Patel, M.R. Regan, C. Haenggeli, Y.H. Huang, D.E.
Bergles, L. Jin, M. Dykes Hoberg, S. Vidensky, D.S. Chung, S.V. Toan,
L.I. Bruijn, Z.Z. Su, P. Gupta, P.B. Fisher, Beta-lactam antibiotics offer
neuroprotection by increasing glutamate transporter expression, Nature
433 (2005) 73–77.
[38] S. Carpenter, Proximal axonal enlargement in motor neuron diseases,
Neurology 18 (1968) 841–851.
[39] Y. Kawamura, P.J. Dyck, M. Shimono, H. Okazaki, J. Tateishi, H. Doi,
Morphometric comparison of the vulnerability of peripheral motor and
sensory neurons in amyotrophic lateral sclerosis, J. Neuropathol. Exp.
Neurol. 40 (1981) 667–675.
[40] A. Al-Chalabi, P. Andersen, D. Nilsson, B. Chioza, J. Andersson, C.
Russ, C. Shaw, J. Powell, P. Leigh, Deletions of the heavy neurofilament
subunit tail in amyotrophic lateral sclerosis, Hum. Mol. Genet. 8 (1999)
157–164.
[41] Z. Xu, L.C. Cork, J.W. Griffin, D.W. Cleveland, Increased expression of
neurofilament subunit NF-L produces morphological alterations that
resemble the pathology of human motor neuron disease, Cell 73 (1993)
23–33.
[42] M.K. Lee, J. Marszelek, D.W. Cleveland, A mutant neurofilament subunit
causes massive, selective motor neuron death: implications for the
pathogenesis of human motor neuron disease, Neuron 13 (1994)
975–988.
1147A.B. DiBernardo, M.E. Cudkowicz / Biochimica et Biophysica Acta 1762 (2006) 1139–1149[43] F. Cote, J.F. Collard, J.P. Julien, Progressive neuronopathy in transgenic
mice expressing the human neurofilament heavy gene: a mouse model of
amyotrophic lateral sclerosis, Cell 73 (1993) 35–46.
[44] S. Couillard-Despres, J. Meier, J.P. Julien, Extra axonal neurofilaments
do not exacerbate disease caused by mutant Cu,Zn superoxide dismutase,
Neurobiol. Dis. 7 (2000) 462–470.
[45] S. Couillard-Despres, Q. Zhu, P.C. Wong, D.L. Price, D.W. Cleveland, J.P.
Julien, Protective effect of neurofilament heavy gene overexpression in
motor neuron disease induced by mutant superoxide dismutase, Proc. Natl.
Acad. Sci. U. S. A. 95 (1998) 9626–9630.
[46] J. Kong, Z. Xu, Overexpression of neurofilament subunit NF-L and NF-H
extends survival of a mouse model for amyotrophic lateral sclerosis,
Neurosci. Lett. 281 (2000) 72–74.
[47] C. Zhao, J. Takita, Y. Tanaka, M. Setou, T. Nakagawa, S. Takeda, H.
Yang, S. Terada, T. Nakata, Y. Yakei, M. Saito, S. Ytsuji, Y. Hayashi, N.
Hirokawa, Charcot–Marie–Tooth disease type 2A caused by mutation in
a microtubule motor KIF1Bbeta, Cell 105 (2001) 587–597.
[48] J. Robertson, J. Beaulieu, M. Doroudchi, H. Durham, J. Julien, W.
Mushynski, Apoptotic death of neurons exhibiting peripherin aggregates
is mediated by the proinflammatory cytokine tumor necrosis factor-alpha,
J. Cell Biol. 155 (2001) 217–226.
[49] I. Puls, C. Jonnakuty, B. LaMonte, E. Holzbaur, M. Tokito, E. Mann, M.
Floeter, K. Bidus, D. Drayna, S. Oh, R. Brown, C. Ludlow, K. Fischbeck,
Mutant dynactin in motor neuron disease, Nat. Genet. 33 (2003)
455–456.
[50] P.N. Leigh, M. Swash, Cytoskeletalpathology in motor neuron diseases,
in: L.P. Rowland (Ed.), Amyotrophic Lateral Sclerosis and Other Motor
Neuron Diseases, Raven Press, 1991, pp. 3–23.
[51] K. Mather, F.Z. Watts, M. Carroll, P. Whitehead, M. Swash, N. Cairn, J.
Burke, Antibody to an abnormal protein in amyotrophic lateral sclerosis
identifies Lewy body-like inclusions in ALS and Lewy bodies in
Parkinson's disease, Neurosci. Lett. 160 (1993) 13–16.
[52] L.I. Bruijn, M.K. Houseweart, S. Kato, K.L. Anderson, S.D. Anderson,
E. Ohama, A.G. Reaume, R.W. Scott, D.W. Cleveland, Aggregation and
motor neuron toxicity of an ALS-linked SOD1 mutant independent from
wild-type SOD1, Science 281 (1998) 1851–1854.
[53] P. Pasinelli, M. Belford, N. Lennon, B. Bacskai, B. Hyman, D. Trotti, R.J.
Brown, Amyotrophic lateral sclerosis-associated SOD1 mutant proteins
bind and aggregate with Bcl-2 in spinal cord mitochondria, Neuron 43
(2004) 19–30.
[54] M. Watanabe, M. Dykes-Hoberg, V.C. Culotta, D.L. Price, P.C. Wong,
J.D. Rothstein, Histological evidence of protein aggregation in mutant
SOD1 transgenic mice and in amyotrophic lateral sclerosis neural
tissues, Neurobiol. Dis. 8 (2001) 933–941.
[55] K. Yamanaka, D.W. Cleveland, Determinants of rapid disease
progression in ALS, Neurology 65 (2005) 1859–1860.
[56] T. Sato, T. Nakanishi, Y. Yamamoto, P.M. Andersen, Y. Ogawa, K.
Fukada, Z. Zhou, F. Aoike, F. Sugai, S. Nagano, S. Hirata, M. Ogawa, R.
Nakano, T. Ohi, T. Kato, M. Nakagawa, T. Hamasaki, A. Shimizu, S.
Sakoda, Rapid disease progression correlates with instability of mutant
SOD1 in familial ALS, Neurology 65 (2005) 1954–1957.
[57] H. Durham, J. Roy, L. Doug, D. Figlewicz, Aggregation of mutant Cu/Zn
superoxide dismutase proteins in a culture model of ALS, J. Neuropathol.
Exp. Neurol. 56 (1997) 523–530.
[58] Y.J. Patel, M.D. Payne Smith, J. de Belleroche, D.S. Latchman, Hsp27
and Hsp70 administered in combination have a potent protective effect
against FALS-associated SOD1-mutant-induced cell death in mammalian
neuronal cells, Brain Res. Mol. Brain Res. 134 (2005) 256–274.
[59] H. Takeuchi, Y. Kobayashi, T. Yoshihara, J. Niwa, M. Doyu, K. Ohtsuka,
G. Sobue, Hsp70 and Hsp40 improve neurite outgrowth and suppress
intracytoplasmic aggregate formation in cultured neuronal cells
expressing mutant SOD1, Brain Res. 949 (2002) 11–22.
[60] D. Kieran, B. Kalmar, J.R. Dick, J. Riddoch-Contreras, G. Burnstock, L.
Greensmith, Treatment with arimoclomol, a coinducer of heat shock
proteins, delays disease progression in ALS mice, Nat. Med. 10 (2004)
402–405.
[61] Z. Batulan, G.A. Shinder, S. Minotti, B.P. He, M.M. Doroudchi, J.
Nalbantoglu, M.J. Strong, H.D. Durham, High threshold for induction ofthe stress response in motor neurons is associated with failure to activate
HSF1, J. Neurosci. 23 (2003) 5789–5798.
[62] M.C. Dal Canto, M.E. Gurney, Neuropathological changes in two lines of
mice carrying a transgene for mutant human Cu/Zn SOD, and in mice
overexpressing wild type human SOD: a model of familial amyotrophic
lateral sclerosis (FALS), Brain Res. 676 (1994) 25–40.
[63] J. Kong, Z. Xu, Massive mitochondrial degeneration in motor neurons
triggers the onset of amyotrophic lateral sclerosis in mice expressing a
mutant SOD1, J. Neurosci. 18 (1998) 3241–3250.
[64] D. Jaarsma, Swelling and vacuolisation of mitochondria in transgenic
SOD1-ALS mice: a consequence of supranormal SOD1 expression?
Mitochondrion 6 (2006) 48–49.
[65] M. Mattiazzi, M. D'Aurelio, C.D. Gajewski, K. Martushova, M. Kiaei,
M.F. Beal, G. Manfredi, Mutated human SOD1 causes dysfunction of
oxidative phosphorylation in mitochondria of transgenic mice, J. Biol.
Chem. 277 (2002) 29626–29633.
[66] S. Zhu, I.G. Stavrovskaya, M. Drozda, B.Y. Kim, V. Ona, M. Li, S.
Sarang, A.S. Liu, D.M. Hartley, C. Wu du, S. Gullans, R.J. Ferrante, S.
Przedborski, B.S. Kristal, R.M. Friedlander, Minocycline inhibits
cytochrome c release and delays progression of amyotrophic lateral
sclerosis in mice, Nature 417 (2002) 74–78.
[67] F.M. Menzies, P.G. Ince, P.J. Shaw, Mitochondrial involvement in
amyotrophic lateral sclerosis, Neurochem. Int. 40 (2002) 543–551.
[68] K. Fukada, F. Zhang, A. Vien, N.R. Cashman, H. Zhu, Mitochondrial
proteomic analysis of a cell line model of familial amyotrophic lateral
sclerosis, Mol. Cell Proteomics 3 (2004) 1211–1223.
[69] Y. Masui, T. Mozai, K. Kakehi, Functional and morphometric study of the
liver in motor neuron disease, J. Neurol. 232 (1985) 15–19.
[70] K. Nakano, K. Hirayama, K. Terai, Hepatic ultrastructural changes and
liver dysfunction in amyotrophic lateral sclerosis, Arch. Neurol. 44
(1987) 103–106.
[71] L. Siklos, J. Engelhardt, Y. Harati, R. Smith, F. Joo, S. Appel,
Ultrastructural evidence for altered calcium in motor nerve terminals in
amyotrophic lateral sclerosis, Ann. Neurol. 39 (1996) 203–219.
[72] G.K. Dhaliwal, R.P. Grewal, Mitochondrial DNA deletion mutation
levels are elevated in ALS brains, NeuroReport 11 (2000) 2507–2509.
[73] F. Wiedemann, K. Winkler, A. Kuznetsov, C. Bartels, S. Vielhaber, H.
Feistner, W. Kunz, Impairment of mitochondrial function in skeletal
muscle of patients with amyotrophic lateral sclerosis, J. Neurol. Sci. 156
(1998) 65–72.
[74] G.M. Borthwick, M.A. Johnson, P.G. Ince, P.J. Shaw, D.M. Turnbull,
Mitochondrial enzyme activity in amyotrophic lateral sclerosis:
implications for the role of mitochondria in neuronal cell death, Ann.
Neurol. 46 (1999) 787–790.
[75] R.H. Swerdlow, J.K. Parks, D.S. Cassarino, P.A. Trimmer, S.W. Miller,
D.J. Maguire, J.P. Sheehan, R.S. Maguire, G. Pattee, V.C. Juel, L.H.
Phillips, J.B. Tuttle, J.P. Bennett Jr., R.E. Davis, W.D. Parker Jr.,
Mitochondria in sporadic amyotrophic lateral sclerosis, Exp. Neurol. 153
(1998) 135–142.
[76] C.D. Gajewski, M.T. Lin, M.E. Cudkowicz, M.F. Beal, G. Manfredi,
Mitochondrial DNA from platelets of sporadic ALS patients restores
normal respiratory functions in rho(0) cells, Exp. Neurol. 179 (2003)
229–235.
[77] L. Martin, Neuronal death in amyotrophic lateral sclerosis is apoptotic:
possible contribution of programmed cell death mechanism, J. Neuropathol.
Exp. Neurol. 58 (1999) 459–471.
[78] Y. Yoshiyama, T. Yamada, K. Asanuma, T. Asahi, Apoptosis related
antigen, LeYand nick-end labeling are positive in spinal motor neurons in
amyotrophic lateral sclerosis, Acta Neuropathol. 88 (1994) 207–211.
[79] W.A. Pedersen, H. Luo, I. Kruman, E. Kasarskis, M.P. Mattson, The
prostate apoptosis response-4 protein participates in motor neuron
degeneration in amyotrophic lateral sclerosis, FASEB J. 14 (2000)
913–924.
[80] X. Mu, J. He, D. Anderson, J. Trojanowski, J. Springer, Altered
expression of bcl-2 and bax mRNA in amyotrophic lateral sclerosis spinal
cord motor neurons, Ann. Neurol. 40 (1996) 379–386.
[81] M.R. Cookson, P.J. Shaw, Oxidative stress and motor neurone disease,
Brain Pathol. 9 (1999) 165–186.
1148 A.B. DiBernardo, M.E. Cudkowicz / Biochimica et Biophysica Acta 1762 (2006) 1139–1149[82] M. Li, V.O. Ona, C. Guegan, M. Chen, V. Jackson-Lewis, L.J. Andrews,
A.J. Olszewski, P.E. Stieg, J.P. Lee, S. Przedborski, R.M. Friedlander,
Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse
model, Science 288 (2000) 335–339.
[83] S. Vukosavic, L. Stefanis, V. Jackson-Lewis, C. Guegan, N. Romero, C.
Chen, M. Dubois-Duphin, S. Przedborski, Delaying caspase activation of
Bcl-2: a clue to disease retardation in a transgenic mouse model of
amyotrophic lateral sclerosis, J. Neurosci. 20 (2000) 9119–9125.
[84] V. Kostic, V. Jackson-Lewis, F. de Bilbao, M. Dubois-Dauphin, S.
Przedborski, Bcl-2: prolonging life in a transgenic mouse model of
familial amyotrophic lateral sclerosis, Science 277 (1997) 559–562.
[85] S. Sathasivam, A.J. Grierson, P.J. Shaw, Characterization of the caspase
cascade in a cell culture model of SOD1-related familial amyotrophic
lateral sclerosis: expression, activation and therapeutic effects of
inhibition, Neuropathol. Appl. Neurobiol. 31 (2005) 467–485.
[86] W. Wan, P.B. DePetrillo, Ritonavir protects hippocampal neurons
against oxidative stress-induced apoptosis, Neurotoxicology 23 (2002)
301–306.
[87] M.E. Alexianu, M. Kozovska, S.H. Appel, Immune reactivity in a mouse
model of familial ALS correlates with disease progression, Neurology 57
(2001) 1282–1289.
[88] T. Kawamata, H. Akiyama, T. Yamada, P.L. McGeer, Immunologic
reactions in amyotrophic lateral sclerosis brain and spinal cord tissue,
Am. J. Pathol. 140 (1992) 691–707.
[89] E. Hall, P. Andrus, J. Oostveen, T. Fleck, M. Gurney, Relationship of
oxygen radical-induced lipid peroxidative damage to disease onset and
progression in a transgenic model of familial ALS, J. Neurosci. Res. 53
(1998) 66–77.
[90] M.D. Nguyen, T. D'Aigle, G. Gowing, J.P. Julien, S. Rivest,
Exacerbation of motor neuron disease by chronic stimulation of innate
immunity in a mouse model of amyotrophic lateral sclerosis, J. Neurosci.
24 (2004) 1340–1349.
[91] T. Sekizawa, H. Openshaw, K. Ohbo, K. Sugamura, Y. Itoyama, J.C.
Niland, Cerebrospinal fluid interleukin 6 in amyotrophic lateral sclerosis:
immunological parameter and comparison with inflammatory and non-
inflammatory central nervous system diseases, J. Neurol. Sci. 154 (1998)
194–199.
[92] G. Almer, N. Romero, S. Przedborski, Upregulation of cyclooxygenase-2
in an animal model of familial amyotrophic lateral sclerosis, Neurology
54 (2000) A304.
[93] A. Malaspina, N. Kaushik, J. de Belleroche, Differential expression of 14
genes in amyotrophic lateral sclerosis spinal cord detected using gridded
cDNA arrays. J. Neurochem. 77 (2001) 132–145.
[94] K. Hensley, J. Fedynyshyn, S. Ferrell, R.A. Floyd, B. Gordon, P.
Grammas, L. Hamdheydari, M. Mhatre, S. Mou, Q.N. Pye, C. Stewart,
M. West, S. West, K.S. Williamson, Message and protein-level elevation
of tumor necrosis factor alpha (TNF alpha) and TNF alpha-modulating
cytokines in spinal cords of the G93A-SOD1 mouse model for
amyotrophic lateral sclerosis, Neurobiol. Dis. 14 (2003) 74–80.
[95] T. Tikka, J. Koistinaho, Minocycline provides neuroprotection against N-
methyl-D-aspartate neurotoxicity by inhibiting microglia, J. Immunol.
166 (2001) 7527–7533.
[96] T. Tikka, B. Fiebich, G. Goldsteins, R. Keinanen, J. Koistinaho, Minocycline,
a tetracycline derivative, is neuroprotective against excitotoxicity by
inhibiting activation and proliferation of microglia, J. Neurosci. 21 (2001)
2580–2588.
[97] J. Yrjanheikki, T. Tikka, R. Keinanen, G. Goldsteins, P. Chan, J.
Koistinaho, A tetracycline derivative, minocycline, reduces inflammation
and protects against focal cerebral ischemia with a wide therapeutic
window, Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 13496–13500.
[98] S. Zhu, I. Stavrovskiaya, M. Drozda, K. BY, V. Ona, M. Li, S. Sarang, A.
Liu, D. Hartley, D. Wu, S. Gullans, R. Ferrante, S. Przedborski, B.
Kristal, R. Friedlander, Minocycline inhibits cytochrome c release and
delays progression of amyotrophic lateral sclerosis in mice, Nature 417
(2002) 74–78.
[99] J. Kriz, M.D. Nguyen, J.P. Julien, Minocycline slows disease progression
in a mouse model of amyotrophic lateral sclerosis, Neurobiol. Dis. 10
(2002) 268–278.[100] A. Pramatarova, J. Laganiere, J. Roussel, K. Brisebois, G.A. Rouleau,
Neuron-specific expression of mutant superoxide dismutase 1 in
transgenic mice does not lead to motor impairment, J. Neurosci. 21
(2001) 3369–3374.
[101] M. Lino, C. Schneider, P. Caroni, Accumulation of SOD1 mutants in
postnatal motoneurons does not cause motoneuron pathology or
motoneuron disease, J. Neurosci. 22 (2002) 4825–4832.
[102] A. Clement, M. Nguyen, E. Roberts, M. Garcia, S. Boillée, M. Rule, A.
McMahon, W. Doucette, D. Siwek, R. Ferrante, R. Brown, J. Julien, L.
Goldstein, D. Cleveland, Wild-type nonneuronal cells extend survival of
SOD1 mutant motor neurons in ALS mice, Science 3 (2003 Oct)
113–117.
[103] J.P. Crow, N.Y. Calingasan, J. Chen, J.L. Hill, M.F. Beal, Manganese
porphyrin given at symptom onset markedly extends survival of ALS
mice, Ann. Neurol. 58 (2005) 258–265.
[104] A.L. Moreira, E.P. Sampaio, A. Zmuidzinas, P. Frindt, K.A. Smith, G.
Kaplan, Thalidomide exerts its inhibitory action on tumor necrosis factor
alpha by enhancing mRNA degradation, J. Exp. Med. 177 (1993)
1675–1680.
[105] W. Camu, C. Henderson, Rapid purification of embryonic rat
motoneurons: an in vitron model for studying MND/ALS pathogenesis,
J. Neurol. Sci. 124 (1994) 73–74 (Suppl).
[106] W. Vandenberghe, L. Van Den Bosch, W. Robberecht, Glial cells
potentiate kainate-induced neuronal death in a motoneuron-enriched
spinal coculture system, Brain Res. 807 (1998) 1–10.
[107] J.D. Rothstein, L. Lin, M. Dykes-Hoberg, R.W. Kuncl, Chronic inhibition
of glutamate uptake produces a model of slow motor neuron toxicity,
Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 6591–6595.
[108] F.M. Menzies, M.R. Cookson, R.W. Taylor, D.M. Turnbull, Z.M.
Chrzanowska-Lightowlers, L. Dong, D.A. Figlewicz, P.J. Shaw,
Mitochondrial dysfunction in a cell culture model of familial
amyotrophic lateral sclerosis, Brain 125 (2002) 1522–1533.
[109] O. Elroy-Stein, Y. Bernstein, Y. Grner, Overproduction of human Cu/Zn-
superoxide dismutase in transfected cells: extenuation of paraquat-
mediated cytotoxicity and enhancement of lipid peroxidation, EMBO J. 5
(1986) 615–622.
[110] J.D. Rothstein, Of mice and men: reconciling preclinical ALS mouse
studies and human clinical trials, Ann. Neurol. 53 (2003) 423–426.
[111] J. Heemskerk, A.J. Tobin, B. Ravina, From chemical to drug:
neurodegeneration drug screening and the ethics of clinical trials, Nat.
Neurosci. 5 (2002) 1027–1029 (Suppl).
[112] M. Tsacopoulos, P.J. Magistretti, Metabolic coupling between glia and
neurons, J. Neurosci. 16 (1996) 877–885.
[113] C. Desnuelle, M. Dib, C. Garrel, A. Favier, ALS riluzole-tocopherol
Study Group, A double-blind, placebo-controlled randomized clinical
trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic
lateral sclerosis, Amyotroph. Lateral Scler. Other Motor Neuron Disord. 2
(2001) 9–18.
[114] R.G. Miller, D.H. Moore, D.F. Gelinas, B. Dronsky, M. Mendoza, R.
Barohn, W. Bryan, J. Ravits, E. Yuen, H. Neville, S. Ringel, M.
Bromberg, J. Petajan, A. Amato, C. Jackson, W. Johnson, R. Mandler, P.
Bosch, B. Smith, M. Graves, M. Ross, E.J. Sorenson, P. Kelkar, G. Parry,
R. Olney, W.A.S. Group, Phase III randomized trial of gabapentin in
patients with amyotrophic lateral sclerosis, Neurology 56 (2001)
843–848.
[115] M. Cudkowicz, J. Shefner, D. Schoenfeld, R.J. Brown, H. Johnson, M.
Qureshi, M. Jacobs, J. Rothstein, S. Appel, R. Pascuzzi, T. Heiman-
Patterson, P. Donofrio, W. David, J. Russell, R. Tandan, E. Pioro, K.
Felice, J. Rosenfeld, R. Mandler, G. Sachs, W. Bradley, E. Raynor, G.
Baquis, J. Belsh, S. Novella, J. Goldstein, J. Hulihan, A randomized,
placebo-controlled trial of topiramate in amyotrophic lateral sclerosis,
Neurology 61 (2003) 456–464.
[116] M. Cudkowicz, 15th International Symposium on ALS/MND,
Philadelphia, 2004.
[117] J. Shefner, M. Cudkowicz, D. Schoenfeld, C. T, J. Taft, M. Chilton, L.
Urbinelli, H. Zhang, A. Pestronk, J. Caress, E. Sorenson, W. Bradley, C.
Lomen-Hoerth, E. Pioro, K. Rezania, M. Ross, R. Pascuzzi, T. Heiman-
Patterson, R. Tandan, H. Mitsumoto, J. Rothstein, T. Smith-Palmer, D.
1149A.B. DiBernardo, M.E. Cudkowicz / Biochimica et Biophysica Acta 1762 (2006) 1139–1149MacDonald, D. Burke, NEALS Consortium, A clinical trial of creatine in
amyotrophic lateral sclerosis, Neurology 63 (2004) 1656–1661.
[118] M.C. DalCanto, M.E. Gurney, Neuropathological changes in two lines of
mice carrying a transgene for mutant human CU,Zn SOD, and in mice
overexpressing wild type human SOD: a model of familial amyotrophic
lateral sclerosis (FALS), Brain Res. 676 (1994) 25–40.
[119] P. Klivenyi, R. Ferrante, R. Matthew, M. Bogdanov, A. Klein, G. Mueller,
M. Wermer, R. Kaddurah-Daouk, M. Beal, A. OA, Neuroprotective
effects of creatine in a transgenic animal model of ALS, Nat. Med. 5
(1999) 347–350.
[120] G. Groeneveld, J. Veldink, I. van der Tweel, S. Kalmijn, C. Beijer, M.
de Visser, J. Wokke, H. Franssen, L. van den Berg, A randomized
sequential trial of creatine in amyotrophic lateral sclerosis, Ann. Neurol.
53 (2003) 437–445.
[121] P.H. Gordon, R.G. Miller, D.H. Moore, ALSFRS-R, Amyotroph. Lateral.
Scler. Other Mot. Neuron Disord. 5 (Suppl 1) (2004) 90–93.
[122] B.J. Traynor, H. Zhang, J.M. Shefner, D. Schoenfeld, M.E. Cudkowicz,
Functional outcome measures as clinical trial endpoints in ALS,
Neurology 63 (2004) 1933–1935.
[123] D. Schoenfeld, Statistical considerations for pilot studies, Int. J. Radiat.
Oncol. Biol. Phys. 6 (1980) 371–374.
[124] A controlled trial of recombinant methionyl human BDNF in ALS: The
BDNF Study Group (Phase III), Neurology 52 (1999) 1427–1433.
[125] M. Cudkowicz, M. Qureshi, J. Shefner, Measures and markers in
amyotrophic lateral sclerosis, NeuroRx 1 (2004) 284–294.[126] P. Kaufmann, G. Levy, J.L. Thompson, M.L. Delbene, V. Battista, P.H.
Gordon, L.P. Rowland, B. Levin, H. Mitsumoto, The ALSFRSr
predicts survival time in an ALS clinic population, Neurology 64
(2005) 38–43.
[127] V. Meininger, B. Asselain, P. Guillet, P.N. Leigh, A. Ludolph, L.
Lacomblez, W. Robberecht, Pentoxifylline in ALS: a double-blind,
randomized, multicenter, placebo-controlled trial, Neurology 66 (2006)
88–92.
[128] K. Felice, A longitudinal study comparing thenar motor unit number
estimates to other quantitative tests in patients with amyotrophic lateral
sclerosis, Muscle Nerve 20 (1997) 179–185.
[129] E.C. Yuen, R.K. Olney, Longitudinal study of fiber density and motor unit
number estimate in patients with amyotrophic lateral sclerosis, Neurology
49 (1997) 573–578.
[130] S. Ranganathan, K. Jordan, R. Sathanoonri, S. Henry, P. Wood, L.
Urbinelli, M. Cudkowicz, R. Brown, R. Bowser, Identification of ALS
specific biomarkers by protein profiling of cerebral spinal fluid, ALS
Motor Neuron Dis. 4 (2003) 12.
[131] C.M.c.-f.a. Rozen S, M. Bogdanov, et al., Metabolomic analysis
and signatures in motor neuron disease, Metabolomics 1 (2005)
101–108.
[132] T. Munsat, J. Taft, I. Jackson, P. Andres, D. Hollander, L. Skerry, M.
Ordman, D. Kadson, Intrathecal thyrotropin-releasing hormone does not
alter the progressive course of ALS: experience with an intrathecal drug
delivery system, Neurology 42 (1992) 1049–1053.
